Dr. Shamoon is Associate Dean for Clinical and Translational Research, Director of the Harold and Muriel Block Institute for Clinical & Translational Research at Einstein and Montefiore (ICTR), and tenured Professor of Medicine (Endocrinology, Diabetes and Metabolism).
The ICTR is home to the Clinical and Translational Science Award (CTSA) program funded by the NIH's National Center for Advancing Translational Sciences (NCATS). The CTSA consortium, a group of ~60 leading US medical research institutions works together to improve the way biomedical research is conducted, and shares a common vision of accelerating laboratory discoveries and engaging communities in clinical research to bring discoveries and prevention into practice. It is also focusing on the training the next generation of clinical investigators. The ICTR represents the research partnership between Albert Einstein College of Medicine and the Montefiore Health System that support the CTSA vision. The ICTR is a hub for many collaborations in clinical and translational projects involving Einstein-Montefiore research centers, departments, and faculty.
Dr. Shamoon's research includes laboratory studies of the mechanisms and treatment for defective counterregulation of hypoglycemia in diabetes. His lab was the first to establish the causal link between reduced epinephrine and glucagon secretion and impaired hepatic glucose production in response to hypoglycemia in type 1 diabetes. Further studies elucidated the stimulus-specificity of the responses to hypoglycemia and the resultant defects in glucose counterregulation, the existence of hepatic "autoregulation" by glucose per se, and the role of glucokinase activation in restoring impaired counterregulation in diabetes. His group has also established the contributions of hepatic glycogen metabolism and gluconeogenesis to glucose counterregulation in humans using in vivo MR spectroscopy, and have examined potential drug targets to restore counterregulatory defenses.
Dr. Shamoon also led major diabetes clinical trials at Einstein, including the Diabetes Control and Complications Trial, the landmark study that established the benefits of intensive glycemic control in type 1 diabetes, and the Diabetes Prevention Program in type 2 diabetes. Dr. Shamoon has been elected to the American Society of Clinical Investigation (ASCI) and the American Association of Physicians (AAP).